Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Shares Outstanding (2018 - 2025)

10x Genomics (TXG) has disclosed Shares Outstanding for 8 consecutive years, with $127.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.42% to $127.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.7 million through Dec 2025, up 4.42% year-over-year, with the annual reading at $127.7 million for FY2025, 4.42% up from the prior year.
  • Shares Outstanding hit $127.7 million in Q4 2025 for 10x Genomics, up from $126.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $127.7 million in Q4 2025 to a low of $109.6 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $117.9 million across 5 years, with a median of $117.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding: rose 11.66% in 2021 and later increased 2.38% in 2022.
  • Year by year, Shares Outstanding stood at $112.5 million in 2021, then increased by 2.38% to $115.2 million in 2022, then grew by 3.39% to $119.1 million in 2023, then increased by 2.68% to $122.3 million in 2024, then rose by 4.42% to $127.7 million in 2025.
  • Business Quant data shows Shares Outstanding for TXG at $127.7 million in Q4 2025, $126.5 million in Q3 2025, and $124.4 million in Q2 2025.